
The above-referenced Abstract, which was published in the August 2015 Cancer Research supplement (1), is being retracted at the request of Acerta Pharma. The Abstract was included in a retrospective review conducted by the sponsor as part of an assessment of research activities. The sponsor worked with several of the authors and the collaborating academic research institute to establish the source of data that contributed to the information in the Abstract. The review demonstrated that no source of the data could be identified to support the statements in the second paragraph of the Abstract. As the source of these data cannot be located, it was determined that these data were not reliable and Acerta Pharma requests retraction of the Abstract.

The authors have agreed to this Retraction.

Reference

Published online September 1, 2017.
doi: 10.1158/0008-5472.CAN-17-2154
©2017 American Association for Cancer Research.

Cancer Res 2017;77:4737.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/77/17/4737

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.